NCT04323956 2026-02-02Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell LymphomaMayo ClinicPhase 1 Active not recruiting50 enrolled
NCT04774068 2025-01-17Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell LymphomasOhio State University Comprehensive Cancer CenterPhase 1 Completed5 enrolled